1. Signaling Pathways
  2. Cytoskeleton
  3. Integrin

Integrin

Integrins, a family of heterodimeric adhesion receptors for diverse extracellular matrices, have consistently been implicated as crucial drivers of ovarian cancer development and progression. A number of the RGD-based members of the integrin family, including α5β1, and αvβ3 or αvβ5 integrins, are markedly elevated in aggressive ovarian tumors. These adhesion receptors appear to promote cell adhesion, survival, motility and invasion during ovarian tumor growth or metastatic progression. Importantly, the functions of these integrins are strongly dependent on the activation of focal adhesion kinase (FAK) and its downstream signaling, including the PI3K/Akt- and Ras/MAPK-dependent pathways.

Integrins are transmembrane proteins and are major receptors for cell-extracellular matrix (ECM) and cell-cell adhesion. Modulation of these molecules, particularly αv integrin family, has exhibited profound effects on fibrosis in multiple organ and disease state. Based on the several studies, the integrins αvβ3, αvβ5, αvβ6, and αvβ8 have been known to modulate the fibrotic process via activation of latent transforming growth factor (TGF)-β in pre-clinical models of fibrosis.

Each integrin is typically formed by the non-covalent pairing of one α subunit, of which, 18 types are known to exist, and one β subunit, of which 8 types are known to exist. Together, 24 distinct heterodimers have been identified to date. The αv subunit can form heterodimers with the β1, β3, β5, β6 or β8 subunits and β1 can associate with many different α subunits from α1 to α11, and αv, indicating that not all theoretically possible α and subunit pairs form. Interestingly, the activation of TGF-β appears to be a common function of multiple αv integrins.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P1408
    Obtustatin
    Inhibitor 99.69%
    Obtustatin is a non-RGD disintegrin of 41 residues. Obtustatin can be isolated from Vipera lebetina obtusa venom. Obtustatin is a potent and selective inhibitor of the adhesion of integrin α1β1 to collagen IV. Obtustatin inhibits angiogenesis, and can be used for research of cancer.
    Obtustatin
  • HY-P1613A
    Cyclo(Arg-Gly-Asp-D-Phe-Val) TFA
    Inhibitor 99.77%
    Cyclo(Arg-Gly-Asp-D-Phe-Val) (TFA) (Cyclo(RGDfV) (TFA))is an integrin αvβ3 inhibitor. Cyclo(Arg-Gly-Asp-D-Phe-Val) (TFA) has antitumor activity. Cyclo(Arg-Gly-Asp-D-Phe-Val) (TFA) can be used for the research of acute myeloid leukemia.
    Cyclo(Arg-Gly-Asp-D-Phe-Val) TFA
  • HY-P0031
    Cyclo(RADfK)
    Modulator
    Cyclo(RADfK) can be used as a control for Cyclo(-RGDfK) (HY-P0023).
    Cyclo(RADfK)
  • HY-P2452
    Vitronectin (367-378)
    99.78%
    Vitronectin (367-378) is a peptide corresponding to residues 367-378 of Vitronectin. Vitronectin is a multifunctional glycoprotein known in several human tumors for its adhesive role in processes such as cell growth, angiogenesis and metastasis.
    Vitronectin (367-378)
  • HY-164768
    LT25
    Agonist 98.73%
    LT25 (compound 17) is a agonist of α5β1 integrin with EC50 value of 9.9 nM.
    LT25
  • HY-P0309A
    Arg-Gly-Glu-Ser TFA
    Control 99.39%
    Arg-Gly-Glu-Ser TFA is a polypeptide related to RGD and is a negative control for Arg-Gly-Asp-Ser (HY-12290).
    Arg-Gly-Glu-Ser TFA
  • HY-70073
    Zaurategrast
    Inhibitor 98.07%
    Zaurategrast (CT7758) is a potent and oral-effective α4-integrin inhibitor.
    Zaurategrast
  • HY-P2532
    Integrin Binding Peptide
    99.73%
    Integrin Binding Peptide is derived by fibronectin. Integrin Binding Peptide can be used for PEG hydrogel preparation.
    Integrin Binding Peptide
  • HY-P2267
    LDV
    Inhibitor 99.27%
    LDV is a non-fluorescent analog of LDV-FITC. LDV is a α4β1 integrin (VLA-4) ligand, and binds α4β1 integrin in leukemia cells.
    LDV
  • HY-P3522
    REDV
    98.29%
    REDV is the minimal active sequence within the CS5 site of the alternatively spliced type III connecting segment (IIICS) region of fibronectin. REDV can mediate adhesion to the IIICS region of plasma fibronectin by binding the integrin alpha 4 beta 1(α4β1). REDV can be used for the research of cell adhesion. REDV is used to study the effects of gene vectors containing REDV on cells.
    REDV
  • HY-148385
    Ganglioside GM2
    98.0%
    Ganglioside GM2 is a human tumor antigen predominantly found in human tumor cells and fetal brain tissue. As a sialylated glycosphingolipid, Ganglioside GM2 is involved in processes such as cell signaling, adhesion, and motility. Ganglioside GM2 abnormal expression and accumulation are associated with tumors and neurodegenerative disorders. Ganglioside GM2 promotes tumor cell migration and invasion by directly binding to the integrin β1 receptor, activating the FAK/Src/Erk-MAPK signaling pathway, and inducing actin cytoskeleton remodeling.
    Ganglioside GM2
  • HY-12308
    TCS 2314
    Antagonist ≥99.0%
    TCS 2314 (compound 3) is orally active and selective very late antigen-4 (VLA-4, α4β1, CD49d/CD29) antagonist with an IC50 of 4.4 nM.
    TCS 2314
  • HY-48959
    α7β1 integrin modulator-1
    Modulator 98.02%
    α7β1 integrin modulator-1 is a potent α7β1 integrin modulator. α7β1 integrin modulator-1 has the potential for the research of muscular dystrophy.
    α7β1 integrin modulator-1
  • HY-P3732
    RGD-4C
    RGD-4C is a arginine-glycine-aspartic acid peptide (ACDCRGDCFC) with integrin binding activity. The Arg-Gly-Asp (RGD) sequence serves as the primary integrin recognition site in extracellular matrix proteins, and peptides containing this sequence can mimic the recognition specificity of the matrix proteins. RGD-4C is a αv-integrin ligand, can conjugate with bioactive molecule to exert antitumor effects in animal models.
    RGD-4C
  • HY-P99296
    Intetumumab
    Inhibitor 99.24%
    Intetumumab (CNTO 95) is a humanized monoclonal antibody targeting CD51/αV-integrins. Intetumumab is used in the research of pancreatic ductal adenocarcinoma (PDAC).
    Intetumumab
  • HY-P0290A
    GRGDSP TFA
    Inhibitor 98.0%
    GRGDSP (TFA) is an integrin inhibitor.
    GRGDSP TFA
  • HY-P99411
    Ontamalimab
    Ontamalimab (SHP647) is a fully-human IgG2 monoclonal antibody targeting mucosal addressin cell adhesion molecule-1 (MAdCAM-1). Ontamalimab can be used for the research of Crohn's disease.
    Ontamalimab
  • HY-P99230
    Pinatuzumab
    Pinatuzumab is a humanized monoclonal antibody targeting cell-surface antigen CD22. Pinatuzumab can be used to synthesize antibody-drug conjugate (ADC) such as Pinatuzumab vedotin (HY-141602). Pinatuzumab can be studied in research on cancer such as non-Hodgkin lymphoma. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
    Pinatuzumab
  • HY-19306
    SB-267268
    Antagonist 99.85%
    SB-267268 is a selective and nonpeptidic alpha(v)beta3 (αvβ3) and alpha(v)beta5 (αvβ5) integrins antagonist, with Kis of 0.9, 0.5 and 0.7 nM for human αvβ3, monkey αvβ3 and human αvβ5, respectively. SB-267268 inhibits human and mouse αvβ3 with IC50s of 0.68 and 0.29 nM, respectively. SB-267268 reduces angiogenesis and VEGF expression.
    SB-267268
  • HY-W588250
    Surfactin C1
    Antagonist 99.36%
    Surfactin C1 is an amphiphilic biosurfactants. Surfactin C1 inhibits leukemic cell (HL-60) adhesion to human umbilical vein endothelial cells (HUVEC). Surfactin C1 inhibits adhesion melecules expression, such as ICAM-1 and VCAM-1.
    Surfactin C1
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.